ACCESSWIRE
27 May 2023, 07:55 GMT+10
NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ('Nascent Biotech', 'Nascent', or the 'Company'), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company and China based BioRay Pharmaceutical Co have mutually agreed to terminate the license agreement entered into on March 31, 2021. Nascent gains back worldwide marketing and distribution rights previously licensed to BioRay. Management concludes with gaining back the worldwide rights, the company is in a stronger position going forward.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.
For further information please visit our website www.nascentbiotech.com.
Forward-Looking Safe Harbor Statement
Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Corporate Contact
Lowell Holden
CFO | Nascent Biotech
[email protected]
SOURCE: Nascent Biotech Inc.
Get a daily dose of The US News news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to The US News.
More InformationWARSAW, Poland: As part of European Union (EU) sanctions imposed against Russia over its invasion of Ukraine, Poland banned all ...
MONTGOMERY, Alabama: Last week, Alabama's school chief, Superintendent Eric Mackey, said that under new reading benchmarks to move to fourth ...
WASHINGTON D.C.: Last week, the Federal Reserve said its losses surpassed the US$100 billion mark and will likely continue to ...
ARLINGTON, Virginia: This week, the U.S. State Department approved the potential sale of drone-related munitions and other systems to Canada ...
BETHESDA, Maryland: This week, the US National Institutes of Health (NIH) said that it started early-stage human trials on FluMos-v2, ...
MAUI, Hawaii: Hawaii Governor Josh Green has announced that the death toll from last month's deadly fire on Maui has ...
NEW YORK: This week, the Wall Street Journal (WSJ) reported that U.S. electric vehicle (EV) maker Tesla and Saudi Arabia ...
NEW YORK, New York - Interest rates could stay higher for longer, but there is the possibility of rate cuts ...
STOCKHOLM, Sweden: Days before the Riksbank, Sweden's central bank, is expected to again raise interest rates, the Swedish krona hit ...
NEW ORLEANS, Louisiana: As Midwest farmers prepare to harvest crops and send tons of grain downriver to the Gulf of ...
JAKARTA, INDONESIA: Government data released this week showed that as imports, such as raw materials and capital goods, declined more ...
NEW YORK, New York - U.S. investors fretted Tuesday while the U.S. central bank deliberated on whether to hike interest ...